Phase 2 N=61 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) or Radiographic Progression — 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,195 Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Prostatic Neoplasms
Primary: Overall Survival — 450.0; 332.0 Days — p=<0.0001
Phase 1 N=34 Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Prostate Adenocarcinoma
Primary: Partial Response in Bone Scan From Baseline to Week 6 — 9; 1; 6 participants
Phase 2 N=36 RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Response Rate — 6 percentage of patients
N/A N=20 Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline
Phase 2 N=21 A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Prostate Cancer · Metastatic Castrate Resistant Prostate Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks
Phase 2 N=13 ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: PSA Decline of >= 50% (PSA50) From Baseline — 7.7 percentage of participants
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants
Phase 2 N=17 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Prostate Cancer
Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants
Phase 1 N=27 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Prostate Cancer · Hormone Refractory Prostate Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants
Phase 2 N=180 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Prostate Cancer Metastatic
Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months
Phase 2 N=170 Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Lymphadenopathy
Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2
Phase 2 N=38 Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
Castration Resistant Prostate Cancer
Primary: Clinical Benefit of NRX 194204 in Men With Castration- and Taxane-resistant Metastatic Prostate Cancer — 19 Participants
Phase 2 N=40 Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Prostate Cancer
Primary: Time to Disease Progression — 15.2 weeks
Phase 3 N=1,028 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Prostate Cancer · Castration Resistant Prostate Cancer · Pain
Primary: Overall Survival (OS) — 11.0; 9.8 months — p=0.213
Phase 2 N=127 Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Prostate Cancer
Primary: Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12 — 47; 89; 88; 22…
Phase 4 N=255 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Prostate Cancer Metastatic
Primary: Radiographic Progression-Free Survival (rPFS) — 8.0; 3.7 months — p=<0.0001
N/A N=25 Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
Prostate Cancer
Primary: Overall Survival (Favorable and Unfavorable ) — 13.9; 36.3 months
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=11 Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Prostate Cancer
Primary: Overall Clinical Benefit — 1; 4; 1; 2 Participants
Phase 2 N=10 Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Prostate Cancer
Primary: Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate — 25 mg/m^2
Phase 2 N=14 Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants
Phase 2 N=67 Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Patients With Gene Alterations — 7; 4; 7; 7 Participants
Phase 2 N=7 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Overall Response Rate (ORR) — 50 percentage of participants
Phase 2 N=36 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma
Primary: Percent of Patients With a Prostate-specific Antigen (PSA) Decline of at Least 50% Below Baseline PSA50 Response Rate — 14 Participants
N/A N=86 Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
Prostate Cancer · Metastasis · Toxicity Due to Radiotherapy
Primary: Median Progression-Free Survival (PFS) — 6.0 months — p=0.001
Phase 3 N=1,088 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 34.66; 30.29 Months
Phase 2 N=9 Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Metastatic Castration-Resistant Prostate Cancer
Primary: Median Time on Treatment — 11 weeks
Phase 2 N=28 Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
Metastatic Castration-resistant Prostate Cancer
Primary: Progression-free Survival (PFS) — 1 Participants
Phase 2 N=9 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Metastatic Castration-resistant Prostate Cancer
Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants